US960914A - Pills for the treatment of diabetes mellitus. - Google Patents

Pills for the treatment of diabetes mellitus. Download PDF

Info

Publication number
US960914A
US960914A US51884009A US1909518840A US960914A US 960914 A US960914 A US 960914A US 51884009 A US51884009 A US 51884009A US 1909518840 A US1909518840 A US 1909518840A US 960914 A US960914 A US 960914A
Authority
US
United States
Prior art keywords
pills
diabetes mellitus
blood
treatment
enzymes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US51884009A
Inventor
Arthur Heinemann
Original Assignee
Arthur Heinemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthur Heinemann filed Critical Arthur Heinemann
Priority to US51884009A priority Critical patent/US960914A/en
Application granted granted Critical
Publication of US960914A publication Critical patent/US960914A/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Description

I liolfirawing.

ARTHUR HEINEMANN, OF LONDON, ENGLAND.

PIL LS FOR THE TREATMENT OF DIABETES MELLITUS.

Specification of Letters Patent.

Application filed September 21, 1909. Serial No. 518,840.

Patented June '7, 1910.

To all whom it'may concern: 7

Be it known that I, ARTHUR HEINEMANN, a subject of the Emperor of Germany, residing at Carlton Mansions, Portsdown Road, Maida Vale, London, W., England, have invented new and useful Improvements in Pills for the Treatment of Diabetes Mellitus, of which the following is a specification.

Diabetes mellitus is a chronic disease of metabolism in which the carbohydrates contained in the food and drink taken by the sufferer are converted into glucose and pass into the urine without contributing to the depend upon the blood for their proper functions it necessarily follows that if the blood can not supply the proper nourishment to said parts the latter will become defective and the blood become charged with abnormal or poisonous matter.

To combat a disease it is necessary to remove its cause. This is effected by the introduction into the blood of a particular substance which in the case of diabetes mellitus must be such as will enable the blood to regain its ability to split up and oxidize the glucose.

The blood, like every other organic matter of vegetable or animal origin, contains enzymes which perform the necessary chemical changes. In the case of diabetes mellitus the blood of the sufferer is not of the proper composition and does not contain either the right or suflicient quantity of enzymes to properly oxidize and assimilate the carbohydrates.

According to my invention I substitute for the natural enzymes, which should be present in the blood, vegetable enzymes,- the socalled oxydases and peroxydaseswhich under certain conditions split up and oxidize the glucose, the products of which are then utilized for the nourishment of the body. But as these enzymes only act in a weak acid or neutral solution and still bet ter in an alkaline solution, and the acid condition of the blood of a diabetic patient is such as to destroy the function,-namely the possibility of utilizing sugar-of even the natural blood enzymes it is necessary to diminish or remove the acidity of the blood. For this Ipurpose I mix the vegetable enzymes wit finely pulverized alkaline salts. The vegetable enzymes and alkaline salts are then formed into pills and coated with keratin or the like, so as to prevent the acids present in the stomach from either reducing or totally annulling the effect of the alkaline enzyme mixture. The pill passes unchanged into the duodenum where it is dissolved by the alkaline liquid present in the intestine. It is then absorbed and passes into the blood, the abnormal amount of acid in the latter being neutralized, so that the natural enzymes of the blood as well as the artificially addedenzymes are able to work under physiological conditions and split up and oxidize the sugar compounds, thus enabling the latter to contribute to the nourishment of the body.

Experience has shown that nearly all vegetable enzymes having an oxidizing effect u on the carbohydrates are useful for the a ove named purpose, especially the oxydases and peroxydases of the genera cucurbita, cochlearia and beta. As regards the alkaline salts to be used those readily absorbed in the intestine such, for instance, as the carbonates of lithium, sodium, potassium and magnesium, and the oxid and peroxid of magnesium should .be employed. Since a peroxydase only acts in the presence of peroxld compounds, it is necessary to always use a peroxld, for example dioxid of magnesium with the peroxydases. The enzyme is prepared from the plant in any suitable or well known manner, such as the following. The leaves, roots or other parts of the plant are inacerated, either with-or without the addition of water, and then if required slightly fermented. The liquid so obtained which contains the enzyme in solution is thenfiltered. and the enzyme successively preci itated and purified by alcohol, ether or ot er suitable means. This constituent is like the corresponding constituent found in yeast and is now known by the same name viz. zymase. The precipitated enzyme or the liquid zymase, as the case may be,

is then mixed with the necessary proportion of alkaline salts and formed mto pills, which are then coated with keratin or other substance incapable of being dissolved by the gastric julce present in the stomach. The pills can be provided with a second coating of such nature as to make them palatable.

In the case of the genus beta the invention could be carried out in the following manner: A suitable quantity of common sugar beets, such for example as 10 kilos is thoroughly cleaned, reduced to a pulp and then subjected to a pressure of, say, 300 atmospheres by means of a suitable hydraulic press. The liquid obtained by this operation, about 7 liters, is then poured into a vessel and mixed with 700 c. c. m. of alcohol of 96% purity, so as to precipitate the sugar and mucous substance contained in the mixture. The liquid in said vessel is removed and filtered, and 45 liters of absolute alcohol added to the filtrate. The resultant precipitate is filtered and Washed with a little absolute alcohol and then placed in a closed vessel. The alcohol is then evaporated preferably at a temperature of about 20 to 30 C. by the withdrawal, by any suitable apparatus, of the air contained in said vessel. The dry powder resulting from the last step, which weighs about 20 grams, is then mixed with 20 grams of magnesium peroxid, 20 ams of lithium carbonate, and 4.8 grams 0 magnesium oxid. This mixture will be sufiicient to form 400 pills or tablets of 0.162 gram, or 24,; grains, each.

I WlSh it to be understood that although I have in the fore oin description advisedly used the wor il it is obvious that the mixture of vegeta le enzymes and alkaline salts may be pressed into the form of small tablets.

Having described my invention, what- I claim and desire to secure by Letters Patent is 1. Pills for the treatment of diabetes mellitus containing a compressed mixture of oxydases and an alkaline salt provided with a coating consistin of a substance insoluble by the gastric juices of the stomach, substantially as described.

2. Pills for the treatment of diabetes mellitus containing a compressed mixture of oxydases of the genus beta and an alkaline salt provided with a coating of' keratin, substantially as described.

,In testimony whereof I have signed my name to this specification in the presence of two subscribing witnesses.

ARTHUR HEINEMANN.

Witnesses: ARTHUR F. ENNIS, F. L. BANDS.

US51884009A 1909-09-21 1909-09-21 Pills for the treatment of diabetes mellitus. Expired - Lifetime US960914A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US51884009A US960914A (en) 1909-09-21 1909-09-21 Pills for the treatment of diabetes mellitus.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51884009A US960914A (en) 1909-09-21 1909-09-21 Pills for the treatment of diabetes mellitus.

Publications (1)

Publication Number Publication Date
US960914A true US960914A (en) 1910-06-07

Family

ID=3029312

Family Applications (1)

Application Number Title Priority Date Filing Date
US51884009A Expired - Lifetime US960914A (en) 1909-09-21 1909-09-21 Pills for the treatment of diabetes mellitus.

Country Status (1)

Country Link
US (1) US960914A (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119089A1 (en) * 2001-09-25 2003-06-26 Dyke Mark Van Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same
US20030219486A1 (en) * 2002-04-10 2003-11-27 Van Dyke Mark E. Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks
US20030224052A1 (en) * 2002-04-22 2003-12-04 Van Dyke Mark E. Hydrogel with controllable merchanical, chemical, and biological properties and method for making same
US20030228353A1 (en) * 2002-01-28 2003-12-11 Keraplast Technologies, Ltd. Bioactive keratin peptides
US20040120910A1 (en) * 2002-04-10 2004-06-24 Dyke Mark Van Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
US6783546B2 (en) 1999-09-13 2004-08-31 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6849092B2 (en) 1999-09-13 2005-02-01 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US20050058686A1 (en) * 2002-07-25 2005-03-17 Mark Van Dyke Bioactive coating for medical devices
US6989437B2 (en) 2002-04-10 2006-01-24 Keraplast Technologies, Ltd. Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
US20070166348A1 (en) * 2005-10-21 2007-07-19 Van Dyke Mark E Keratin bioceramic compositions
US20080089930A1 (en) * 1999-09-13 2008-04-17 Keraplast Technologies, Ltd. Keratin-Based Powders and Hydrogel for Pharmaceutical Applications
US20090004242A1 (en) * 2006-02-17 2009-01-01 Van Dyke Mark E Coatings and Biomedical Implants Formed From Keratin Biomaterials
US20110137329A1 (en) * 2006-02-10 2011-06-09 Dyke Mark E Van Nerve regeneration employing keratin biomaterials
US20110217356A1 (en) * 2010-03-05 2011-09-08 Van Dyke Mark E Controlled delivery system
US20110217285A1 (en) * 2010-03-08 2011-09-08 Van Dyke Mark E Keratin biomaterials for treatment of ischemia
US8258093B2 (en) 2006-02-17 2012-09-04 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US8637231B2 (en) 2004-08-17 2014-01-28 Wake Forest University Health Sciences Method for increasing the volume of a blood substitute with an expander comprising basic alpha keratose
US9068162B2 (en) 2007-08-17 2015-06-30 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
US9220754B2 (en) 2010-11-17 2015-12-29 Wake Forest University Health Sciences Keratin compositions for treatment of bone deficiency or injury

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169963A1 (en) * 1999-09-13 2005-08-04 Southwest Ressearch Institute Implantable prosthetic or tissue expanding device
US20080089930A1 (en) * 1999-09-13 2008-04-17 Keraplast Technologies, Ltd. Keratin-Based Powders and Hydrogel for Pharmaceutical Applications
US6783546B2 (en) 1999-09-13 2004-08-31 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6849092B2 (en) 1999-09-13 2005-02-01 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US20030119089A1 (en) * 2001-09-25 2003-06-26 Dyke Mark Van Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same
US7001988B2 (en) 2001-09-25 2006-02-21 Keraplast Technologies, Ltd. Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same
US20030228353A1 (en) * 2002-01-28 2003-12-11 Keraplast Technologies, Ltd. Bioactive keratin peptides
US7501485B2 (en) 2002-01-28 2009-03-10 Keraplast Technologies, Ltd. Bioactive keratin peptides
US8324346B2 (en) 2002-01-28 2012-12-04 Keraplast Technologies, Ltd. Bioactive keratin peptides
US20110070276A1 (en) * 2002-01-28 2011-03-24 Keraplast Technologies, Ltd. Bioactive keratin peptides
US6989437B2 (en) 2002-04-10 2006-01-24 Keraplast Technologies, Ltd. Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
US6914126B2 (en) 2002-04-10 2005-07-05 Keraplast Technologies, Ltd. Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks
US20030219486A1 (en) * 2002-04-10 2003-11-27 Van Dyke Mark E. Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks
US20040120910A1 (en) * 2002-04-10 2004-06-24 Dyke Mark Van Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
US7001987B2 (en) 2002-04-22 2006-02-21 Keraplast Technologies, Ltd. Hydrogel with controllable mechanical, chemical, and biological properties and method for making same
US20030224052A1 (en) * 2002-04-22 2003-12-04 Van Dyke Mark E. Hydrogel with controllable merchanical, chemical, and biological properties and method for making same
US20050058686A1 (en) * 2002-07-25 2005-03-17 Mark Van Dyke Bioactive coating for medical devices
US20090148488A1 (en) * 2002-07-25 2009-06-11 Keraplast Technologies, Ltd. Bioactive coating for medical devices
US8637231B2 (en) 2004-08-17 2014-01-28 Wake Forest University Health Sciences Method for increasing the volume of a blood substitute with an expander comprising basic alpha keratose
US20070166348A1 (en) * 2005-10-21 2007-07-19 Van Dyke Mark E Keratin bioceramic compositions
US8920827B2 (en) 2005-10-21 2014-12-30 Wake Forest University Health Sciences Keratin bioceramic compositions
US9968706B2 (en) 2006-02-10 2018-05-15 Wake Forest University Health Sciences Nerve regeneration employing keratin biomaterials
US20110137329A1 (en) * 2006-02-10 2011-06-09 Dyke Mark E Van Nerve regeneration employing keratin biomaterials
US8968764B2 (en) 2006-02-10 2015-03-03 Wake Forest University Health Sciences Nerve regeneration employing keratin biomaterials
US20110142910A1 (en) * 2006-02-17 2011-06-16 Van Dyke Mark E Clotting and Healing Compositions Containing Keratin Biomaterials
US8273702B2 (en) 2006-02-17 2012-09-25 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US8299013B2 (en) 2006-02-17 2012-10-30 Wake Forest University Health Sciences Clotting and healing compositions containing keratin biomaterials
US20090004242A1 (en) * 2006-02-17 2009-01-01 Van Dyke Mark E Coatings and Biomedical Implants Formed From Keratin Biomaterials
US9149566B2 (en) 2006-02-17 2015-10-06 Wake Forest University Health Sciences Coatings and biomedical implants formed from keratin biomaterials
US8258093B2 (en) 2006-02-17 2012-09-04 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US9068162B2 (en) 2007-08-17 2015-06-30 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
US20110217356A1 (en) * 2010-03-05 2011-09-08 Van Dyke Mark E Controlled delivery system
US10434213B2 (en) 2010-03-05 2019-10-08 Wake Forest University Health Sciences Controlled delivery system
US8545893B2 (en) 2010-03-08 2013-10-01 Wake Forest University Health Sciences Keratin biomaterials for treatment of ischemia
US20110217285A1 (en) * 2010-03-08 2011-09-08 Van Dyke Mark E Keratin biomaterials for treatment of ischemia
US9220754B2 (en) 2010-11-17 2015-12-29 Wake Forest University Health Sciences Keratin compositions for treatment of bone deficiency or injury

Similar Documents

Publication Publication Date Title
Guthrie et al. Effect of severe undernutrition in early life on growth, brain size and composition in adult rats
Mathews Physiological chemistry
US5612039A (en) Dietary supplement
Gray et al. Pancreatic and extra-pancreatic effects of the traditional anti-diabetic plant, Medicago sativa (lucerne)
EP0025123B1 (en) Polysaccharide rbs substance, process for the production thereof and antitumor agent containing it
US5308618A (en) Dietary fiber extracted from wheat bran pharmaceutical and dietary compositions containing same
US4202969A (en) Method of producing nitrogen-containing polysaccharides
US3973008A (en) Konjac mannan
Chick et al. On the composite nature of the water-soluble B vitamin
EP0056073A1 (en) Process for the preparation of tobacco and tobacco prepared by this process
GB2053176A (en) Spherical particles of activated carbon suitable for use in a pharmaceutical composition
CH635111A5 (en) METHOD FOR PRODUCING ESSENTIAL METAL ION COMPLEXES oligo RESPECTIVELY polygalacturonic.
Choi et al. Antioxidant activity of sulfated polysaccharides isolated from Sargassum fulvellum
US4544550A (en) Method for the treatment of diabetes
CH646874A5 (en) Nutrient solution.
JP4955538B2 (en) Low sodium salt of plant origin
EP0212595B1 (en) Calcium and magnesium complexes of phytohaemagglutinin-polyheteroglycanes, their manufacture and pharmaceutical preparations
US3928322A (en) Konjac mannan
CA2477555A1 (en) Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient
KR20000023394A (en) Enzymatic lysate of lavor and uses thereof
JPH05139984A (en) Active oxygen eliminant from rice
DE3448151C2 (en)
US4229570A (en) Method of producing nitrogen-containing polysaccharides
CN1070804A (en) Process for preparing transparent royal jelly solution
EP1340504B1 (en) Remedies for diabetes